Effectiveness of Spinal Manipulation in Fibromyalgia

Sponsor
Bezmialem Vakif University (Other)
Overall Status
Completed
CT.gov ID
NCT04673058
Collaborator
(none)
60
1
3
9
6.7

Study Details

Study Description

Brief Summary

The aim of this study is to evaluate whether spinal manipulation, which is a potential treatment method for musculoskeletal pain, has an additional contribution in patients with fibromyalgia receiving standard pharmacological treatment.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Spinal Manipulation
  • Procedure: Sham Manipulation
N/A

Detailed Description

Although fibromyalgia (FM) is quite common, success rates in conservative treatment are unsatisfying. Combination of pharmacological and non-pharmacological applications is recommended in treatment. Although the etiology of FM is not well known, characteristic findings such as hyperalgesia and allodynia suggest problems related to pain and sensorial processing in the central nervous system.

It has been suggested that spinal manipulation can alter sensorimotor integration in the central nervous system and therefore can be used in the treatment of central sensitization syndromes. However, manual therapy applications, which were examined under the heading of chiropractic in the 2016 EULAR treatment recommendations, were not recommended due to the low quality (open-label, quasi-experimental) of the studies conducted so far. However, it has been suggested for future studies to investigate whether the combined use of pharmacological and non-pharmacological treatments is more effective than single modality management. But since then unfortunately a high level of evidence also could not be obtained related to use of spinal manipulation in FM due to reasons such as lack of reporting of the manual therapy methods used in detail, conducting studies involving mostly soft tissue techniques and not following CONSORT recommendations.

This study is planned as a prospective, triple-blinding, randomized controlled and 3-arm parallel group design clinical study considering the concepts that have been lacking the literature.

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Prospective, triple-blinding, randomized controlled and 3-arm parallel group design clinical study. 3 arms of the study were planned to consist of active intervention group, sham treatment group and no intervention group.Prospective, triple-blinding, randomized controlled and 3-arm parallel group design clinical study. 3 arms of the study were planned to consist of active intervention group, sham treatment group and no intervention group.
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
2 staff members who will administer the treatment to active intervention and sham therapy groups will not be able to be blinded due the inherent of manual therapy. Staff members who are responsible for statistical analysis, participants and outcome assessors will be blinded.
Primary Purpose:
Treatment
Official Title:
Effectiveness of Spinal Manipulation in Addition to Standard Pharmacological Treatment in Fibromyalgia : A Blinded Randomized Clinical Trial
Actual Study Start Date :
Jan 26, 2021
Actual Primary Completion Date :
Oct 15, 2021
Actual Study Completion Date :
Oct 26, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Spinal Manipulation Group

After the patients were evaluated in terms of somatic dysfunction, the appropriate techniques of Cervical Upglide Thrust, Cervical Downglide Thrust, Cervical Traction Thrust, Cervical Rotation Thrust, Cervico-Thoracic Distraction Manipulation, Cervico-Thoracic Lateral Glide (Spinous Push) Manipulation, Supine Screw Thoracic Thrust, Prone Thoracic Thrust, and Lumbar Spine Rotation Manipulation will be applied to patients.

Procedure: Spinal Manipulation
Intervention will be administered twice a week for 3 weeks. Each treatment session will be given in 20-minute sessions consisting of 10 minutes of manual examination and 10 minutes of manual treatment.
Other Names:
  • high velocity low amplitude thrust manipulation
  • Sham Comparator: Sham Manipulation Group

    A treatment will be applied which is very similar to active treatment but aimed to have minimal therapeutic effect. For this, the practitioner will primarily identify the areas where somatic dysfunction is detected and keep the application away from these areas. The patient will be positioned for treatment as in active therapy, but once in the lock position, a lower thrust will be given by releasing some back from the position. In this way, the movement will be imitated without reaching the elastic zone and a stronger similarity will be provided compared to sham treatments such as light touch or massage.

    Procedure: Sham Manipulation
    The practitioner will primarily identify the areas where somatic dysfunction is detected and keep the application away from these areas. The patient will be positioned for treatment as in active therapy, but once in the lock position, a lower thrust will be given by releasing some back from the position.

    No Intervention: No Intervention Group

    These patients will receive only their pharmacological treatments.

    Outcome Measures

    Primary Outcome Measures

    1. Change from Baseline Pain Intensity at 1 and 3 months [Baseline, one week after the last treatment session (1st month) and 3rd month]

      Patients will be asked to mark their pain on the visual analog scale (VAS) during each visits.

    Secondary Outcome Measures

    1. Change from Baseline Tenderness (tender point pain threshold score) at 1 and 3 months [Baseline, one week after the last treatment session (1st month) and 3rd month]

      Pressure pain threshold of 18 points specified in 1990 American Collage of Rheumatology (ACR) Fibromyalgia classification criteria will be evaluated with The Lafayette Manual Muscle Tester Model 01165 (Lafayette Instrument Company, Lafayette IN, USA). This device is a dynamometer. It has been shown that if circumference is used instead of area as the correction coefficient hand dynamometers with wider tips than standard algometers are also valid and reliable in the pressure pain threshold measurement. The Lafayette Hand-Held Dynamometer uses a tip with a circumference of 5.65 cm. The applied force (kg) / 5.65 will be used as the pressure pain threshold unit in the study. The arithmetic mean of the data obtained from 18 points will be recorded as the tender point pain threshold score.

    2. Change from Baseline Revised Fibromyalgia Impact Questionnaire (FIQR) at 1 and 3 months [Baseline, one week after the last treatment session (1st month) and 3rd month]

      FIQR consists of 3 domains. The first domain contains 9 questions that can be scored between 0 and 10 and the score of the physical function is found by dividing the total score by three. Second domain contains 2 questions and the overall impact score is the sum of the scores from these two questions. Third domain consists of 10 questions and symptom score is obtained by dividing the total score by two. Total FIQR score is the sum of 3 domain points.

    3. Change from Baseline Pain Extent at 1 and 3 months [Baseline, one week after the last treatment session (1st month) and 3rd month]

      The extent of the pain will be evaluated by widespread pain index (WPI). The WPI quantifies the extent of bodily pain on a 0-19 scale by asking patients if they have had pain or tenderness in 19 different body regions (shoulder girdle, hip, jaw, upper arm, upper leg, lower arm, and lower leg on each side of the body, as well as upper back, lower back, chest, neck, and abdomen) over the past week, with each painful or tender region scoring 1 point.

    4. Change from Baseline Fibromyalgia Severity Score (FSS) at 1 and 3 months [Baseline, one week after the last treatment session (1st month) and 3rd month]

      FSS is the sum of the WPI and symptom severity scale (SSS) scores. SSS consists of two domains. For the first domain, the complaints of fatigue, waking unrefreshed and cognitive symptoms are scored between 0 (no problem) and 3 (life-disturbing problems ). For the second domain, headaches, pain or cramps in lower abdomen, and depression are scored between 0 (absent) and 1 (present). The total score gives the SSS score.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 55 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Being diagnosed with fibromyalgia according to the 2016 ACR Fibromyalgia Diagnostic Criteria

    • Having been receiving pharmacological treatment for fibromyalgia for at least 2 weeks

    • VAS pain score> 4

    Exclusion Criteria:
    • Structural problem of the musculoskeletal system (acute spinal disc herniation, acute spondylolisthesis / lysis, fractures and dislocations, advanced degenerative changes, spinal stenosis)

    • Pregnancy or breastfeeding

    • Inflammatory or infectious disease

    • Malignancy

    • Neuromuscular disease

    • History of spinal surgery

    • Unstable psychiatric disease

    • Previously received manual therapy or having enough information about manual therapy to distinguish between sham and real therapy (researched online, watched videos…).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Bezmialem Vakif University Hospital Istanbul Turkey

    Sponsors and Collaborators

    • Bezmialem Vakif University

    Investigators

    • Principal Investigator: Bugra Ince, MD, Bezmialem Vakif University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Bugra Ince, MD Bugra Ince, Bezmialem Vakif University
    ClinicalTrials.gov Identifier:
    NCT04673058
    Other Study ID Numbers:
    • BI031220
    First Posted:
    Dec 17, 2020
    Last Update Posted:
    Oct 27, 2021
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Bugra Ince, MD Bugra Ince, Bezmialem Vakif University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 27, 2021